Business description: Arch Biopartners Inc.

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

Sales by Activity: Arch Biopartners Inc.

Fiscal Period: September 2021 (CAD) 2022 (CAD) 2023 (CAD) 2024 (CAD) 2025 (CAD)

Development of Innovative Technologies

3.89M 965K 1.98M 2.12M 276K

Geographical breakdown of sales: Arch Biopartners Inc.

Fiscal Period: September 2021 (CAD) 2022 (CAD) 2023 (CAD) 2024 (CAD) 2025 (CAD)

Canada

3.89M 965K 1.98M 2.12M 276K

Executive Committee: Arch Biopartners Inc.

Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 03/03/1983
Chief Executive Officer - 03/03/1983
Director of Finance/CFO 60 31/03/2010

Composition of the Board of Directors: Arch Biopartners Inc.

Director TitleAgeSince
Director/Board Member - 06/05/2010
Director/Board Member - 03/03/1983
Director/Board Member 60 31/03/2010
Chairman 62 14/01/2026

Shareholders: Arch Biopartners Inc.

NameEquities%Valuation
14.89 %
9,968,683 14.89 % 8 M $
3.059 %
2,047,619 3.059 % 2 M $
2.917 %
1,952,280 2.917 % 1 M $
1.165 %
780,000 1.165 % 596 700 $
0.3093 %
207,000 0.3093 % 158 355 $

Company details: Arch Biopartners Inc.

Arch Biopartners, Inc.

545 King Street West

M5V 1M1, Toronto

+

http://www.archbiopartners.com
address Arch Biopartners Inc.(ACHFF)

Other Pharmaceuticals

Change 5d. change 1-year change 3-years change Capi.($)
+4.17%+2.00%-50.55%-60.63% 43.01M
-1.68%+0.31%+18.79%+210.92% 926B
+0.23%+1.15%+57.18%+54.19% 586B
-2.47%+2.74%+15.64%+49.30% 412B
+0.16%+3.81%+25.60%+32.26% 382B
+0.55%+5.59%+32.73%+35.58% 326B
-0.44%+4.01%+33.14%+60.33% 317B
-0.72%+1.16%+44.90%+10.65% 302B
+0.45%+1.40%-47.02%-36.77% 218B
+1.18%+2.85%+28.76%+58.25% 201B
Average +0.15%+2.68%+15.92%+41.41% 366.92B
Weighted average by Cap. -0.58%+2.94%+26.54%+81.01%
  1. Stock Market
  2. Equities
  3. ACHFF Stock
  4. Company Arch Biopartners Inc.